Emerging therapies in Huntington’s disease
- 17 June 2019
- journal article
- research article
- Published by Taylor & Francis in Expert Review of Neurotherapeutics
- Vol. 19 (10) , 983-995
Abstract
Introduction Huntington’s disease (HD) is an inherited neurodegenerative condition for which there are no disease-modifying treatments. The availability of early genetic diagnosis makes HD an ideal candidate for early intervention. Growing understanding of pathogenesis has led to identification of new therapeutic targets for which some compounds are now in clinical trials. Areas covered A detailed review of medical databases and clinical trial registries was performed. Recent clinical trials aimed to establish disease-modification were included. Focus was assigned to RNA and DNA-based therapies aimed at lowering mutant huntingtin (mHTT) including antisense oligonucleotides (ASOs), RNA interference (RNAi), zinc finger proteins (ZFPs) and the CRISPR-Cas9 system. Modulation of mHTT and immunotherapies are also covered. Expert opinion Targeting HD pathogenesis at its most proximal level is under intense investigation. ASOs are the only HTT-lowering strategy in clinical trials of manifest HD. Safety and efficacy of an allele specific vs. allele non-specific approach has yet to be established. Success will extend to premanifest carriers for which development of clinical and imaging biomarkers will be necessary. Scientific and technological advancement will bolster new methods of treatment delivery. Cumulative experience, collaborative research and platforms such as ENROLL-HD will facilitate efficient and effective clinical trials.Keywords
This publication has 119 references indexed in Scilit:
- Sigma-1 receptor agonist PRE084 is protective against mutant huntingtin-induced cell degeneration: involvement of calpastatin and the NF-κB pathwayCell Death & Disease, 2013
- Protein aggregates in Huntington's diseaseExperimental Neurology, 2012
- Reduced astrocytic NF-κB activation by laquinimod protects from cuprizone-induced demyelinationActa Neuropathologica, 2012
- Alterations in Brain Transition Metals in Huntington DiseaseArchives of Neurology, 2012
- Preclinical Safety of RNAi-Mediated HTT Suppression in the Rhesus Macaque as a Potential Therapy for Huntington's DiseaseMolecular Therapy, 2011
- HTT haplotypes contribute to differences in Huntington disease prevalence between Europe and East AsiaEuropean Journal of Human Genetics, 2011
- Nonallele-specific Silencing of Mutant and Wild-type Huntingtin Demonstrates Therapeutic Efficacy in Huntington's Disease MiceMolecular Therapy, 2009
- Acetylation Targets Mutant Huntingtin to Autophagosomes for DegradationCell, 2009
- Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: Implications for the therapeutic development of RNAiProceedings of the National Academy of Sciences, 2008
- Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficitsProceedings of the National Academy of Sciences, 2007